Search

Merck & Co Inc.

Cerrado

SectorSanidad

143.93 -0.53

Resumen

Variación precio

24h

Actual

Mínimo

143.65

Máximo

144.57

Métricas clave

By Trading Economics

Ingresos

2.9B

-1.3B

Ventas

321M

17B

P/B

Media del Sector

120.264

56.597

BPA

-0.13

Rentabilidad por dividendo

2.18

Margen de beneficios

-8.051

Empleados

73,000

EBITDA

3.4B

1.4B

Dividendos

By Acuity

Rentabilidad por dividendo

Media del Sector

2.18%

2.18%

Próximas Ganancias

29 oct 2026

Fecha Próximo Dividendo

7 oct 2026

Próxima Fecha de Ex Dividendo

15 sept 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

64B

371B

Apertura anterior

144.46

Cierre anterior

143.93

Noticias sobre sentimiento de mercado

By Acuity

41%

59%

106 / 339 Clasificación en Healthcare

Merck & Co Inc. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 sept 2026, 19:36 UTC

Merck & Co Inc shares are declining amid broader market trends following inflation data that heightened interest rate hike speculation. No specific company news was identified.

10 sept 2026, 20:07 UTC

News

Merck & Co Inc shares are lower today despite HSBC raising its price target to $172 and noting insider buying activity.

9 sept 2026, 19:36 UTC

News

Merck & Co. shares are lower after a court upheld Medicare's drug-price negotiations, raising concerns about future prescription drug spending.

8 sept 2026, 23:06 UTC

News

Merck & Co. shares are higher after Karim Mikhail's appointment to lead the FDA's Center for Biologics Evaluation and Research, boosting the company's regulatory reputation.

4 sept 2026, 23:05 UTC

Merck & Co Inc shares are higher in after-market trading, despite no specific news. Broader market signals show mixed economic indicators and rising Treasury yields.

3 sept 2026, 23:05 UTC

Merck & Co Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid broader market gains.

2 sept 2026, 19:46 UTC

Social Media
News

Merck & Co Inc is rising following positive results from the ATLAS-UC Phase 3 trial, which met its primary endpoint of clinical significance.

1 sept 2026, 23:07 UTC

Merck & Co Inc. shares were roughly flat during after-market hours, with no specific company news identified amid broader market fluctuations driven by rising oil prices.

31 ago 2026, 23:16 UTC

Merck & Co Inc shares are trading higher in after-market hours. Broader market sentiment is influenced by escalating geopolitical tensions and inflation concerns.

28 ago 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market trading, supported by rising Treasury yields and trading above their 20-day moving average.

27 ago 2026, 23:01 UTC

Merck & Co Inc. shares are higher in after-market trading, reflecting routine performance despite three consecutive lower sessions. The stock remains above its 20-day moving average.

26 ago 2026, 23:11 UTC

Merck & Co Inc is higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25 ago 2026, 23:06 UTC

Social Media

Merck & Co Inc reached all-time highs in after-market trading, gaining over $6 amid positive social media sentiment and broader market dynamics.

24 ago 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

21 ago 2026, 19:31 UTC

News
Social Media

Merck & Co Inc shares are higher today as Goldman Sachs and Morgan Stanley upgraded their ratings and raised price targets, citing confidence in cancer treatments.

20 ago 2026, 19:31 UTC

News
Social Media
Event

Merck & Co Inc shares are lower today following downgrades from RBC Capital and UBS, with both firms setting a price target of $150.

19 ago 2026, 23:41 UTC

Event
Social Media

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

17 ago 2026, 19:36 UTC

News

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

15 ago 2026, 00:01 UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

14 ago 2026, 23:21 UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

13 ago 2026, 23:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

12 ago 2026, 19:56 UTC

News

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

11 ago 2026, 19:36 UTC

News

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.

10 ago 2026, 19:36 UTC

Social Media
News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7 ago 2026, 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

6 ago 2026, 23:01 UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

5 ago 2026, 19:43 UTC

News
Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

4 ago 2026, 23:26 UTC

News

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

3 ago 2026, 20:03 UTC

News
Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31 jul 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

Comparación entre iguales

Cambio de precio

Merck & Co Inc. previsión

Consenso

By TipRanks

Compra Moderada

19 ratings

14

Comprar

5

Mantener

0

Vender

Sentimiento

By Acuity

106 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.